companies

Neurescue

Founded 2014
Employees 10+
Primary contact
Koebmagergade 53, 2.
1150 Copenhagen
Denmark
Links
https://neurescue.com/
Neurescue has developed what it claims to be the world's first intelligent balloon catheter for aortic occlusion, which is an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The NEURESCUE device includes a catheter and a control unit with patented sensor guidance and automated inflation technology, and is meant to be inserted through the femoral artery to temporarily inflate a soft balloon in the aorta to redirect blood flow towards the upper body. The goal of this procedure is to deliver additional time to control blood loss and bridge patients to additional life-saving treatment options.
Founded 2014
Employees 10+
Primary contact
Koebmagergade 53, 2.
1150 Copenhagen
Denmark
Links
https://neurescue.com/

Funding 💰

Total $3.7M
Select investors Seed Capital, Nina Capital

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • The problem it tackles: The current standard of care for cardiac arrest is cardiopulmonary resuscitation (CPR) with chest compressions and defibrillation. Today's CPR only replaces 35% of blood flow to the heart and the brain, which is not high enough to resuscitate the majority of patients and does not provide enough time to successfully bridge most patients to advanced definitive treatments.
  • Increasing the survival rate: Today, only 1 out of 10 survive a cardiac arrest with the current treatment and it is estimated to be the single largest cause of death worldwide. Neurescue aims for its device to help increase the survival rate for these patients.
  • Designed for emergency use: With a portable package and a minimal number of user steps to a successful occlusion, the NEURESCUE device is designed for the emergency setting.
  • Ready for America: In June 2021, Neurescue secured 510(k) clearance from the US FDA for its intelligent balloon catheter for aortic occlusion. At the time, the company also received FDA approval for the investigational device exemption (IDE) application to begin a clinical study of a novel cardiac arrest treatment indication.

Video ▶️

Awards & Recognitions 🏆

  • 2020 Among MedTech Innovator's Top 50 Showcase companies 🔗
  • 2017 Forbes 30 Under 30: Europe - Technology 🔗

Quotes 💬

“
The NEURESCUE device represents a significant advancement that could meaningfully improve the survival rates for emergency patients. The device gives patients suffering traumatic blood loss a longer window of time to receive appropriate medical interventions, which can directly translate to saved lives.
— Maham Rahimi, M.D., Ph.D., assistant professor of cardiovascular surgery at Weill Cornell School of Medicine 🔗
“
Seventy-five percent of patients with cardiac arrest die because they don't respond to current standard treatments of cardiopulmonary resuscitation (CPR), defibrillation and medicine. This device gives us an extended chance at saving a life.
— David Shavelle, M.D., medical director of adult cardiology and interventional lab at MemorialCare Heart & Vascular Institute, Long Beach Medical Center 🔗
Last update: August 23, 2022